BDTX 1535
Alternative Names: BDTX-1535Latest Information Update: 06 Jun 2024
At a glance
- Originator Black Diamond Therapeutics
- Developer Barrow Neurological Institute; Black Diamond Therapeutics; St Josephs Hospital and Medical Center; The Ivy Brain Tumor Center
- Class 2 ring heterocyclic compounds; Amides; Amines; Aniline compounds; Antineoplastics; Halogenated hydrocarbons; Morpholines; Quinazolines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Glioblastoma; Non-small cell lung cancer
- Phase 0 Glioma
Most Recent Events
- 01 Jun 2024 Adverse event, efficacy, pharmacokinetics and pharmacodynamics data from a phase I trial in Non-small cell lung cancer and Glioblastoma released by Black Diamond Therapeutics
- 31 May 2024 Pharmacokinetic and adverse events data from a phase 0 trial in Glioma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 updated efficacy and adverse events from a phase I/II trial in Non-Small Cell Lung Cancer and Glioblastoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)